Page 14 - Read Online

Page 192 Paraskevas. Neuroimmunol Neuroinflammation 2020;7:183-93 I http://dx.doi.org/10.20517/2347-8659.2019.008

74. Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, et al. NIA-AA Research Framework: Toward a biological definition of
Alzheimer’s disease. Alzheimers Dement 2018;14:535-62.
75. van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, et al. Cerebrospinal fluid Alzheimer’s disease biomarkers across the
spectrum of Lewy body diseases: results from a large multicenter cohort. J Alzheimers Dis 2016;54:287-95.
76. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, et al. Diagnosis and management of dementia with Lewy bodies: Fourth
consensus report of the DLB Consortium. Neurology 2017;89:88-100.
77. Skogseth R, Hortobágyi T, Soennesyn H, Chwiszczuk L, Ffytche D, et al. Accuracy of clinical diagnosis of dementia with Lewy bodies
versus neuropathology. J Alzheimers Dis 2017;59:1139-52.
78. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, et al Sensitivity of revised diagnostic criteria for the behavioural variant
of frontotemporal dementia. Brain 2011;134:2456-77.
79. Lleó A, Irwin DJ, Illán-Gala I, McMillan CT, Wolk DA, et al. A 2-Step Cerebrospinal algorithm for the selection of frontotemporal lobar
degeneration subtypes. JAMA Neurol 2018;75:738-45.
80. Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J. Neurochemical dementia diagnostics: a simple algorithm for interpretation of the
CSF biomarkers. J Neural Transm 2009;116:1163-7.
81. Lewczuk P, Kornhuber J, Toledo JB, Trojanowski JQ, Knapik-Czajka M, et al. Validation of the Erlangen score algorithm for the
prediction of the development of dementia due to Alzheimer’s disease in pre-dementia subjects. J Alzheimers Dis 2015;48:433-41.
82. Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF
biomarkers amyloid β(1-42), tau, and phosphorylated tau in Alzheimer’s disease: report of an international workshop. Int J Alzheimers
Dis 2010;2010:635053.
83. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, et al. The Alzheimer’s Association external quality control program for
cerebrospinal fluid biomarkers. Alzheimers Dement 2011;7:386-95.e6.
84. Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM. Clinical utility and analytical challenges in measurement of cerebrospinal
fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers. Clin Chem 2013;59:903-16.
85. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, et al.; Alzheimer’s Association QC Program Work Group. CSF biomarker
variability in the Alzheimer’s Association quality control program. Alzheimers Dement 2013;9:251-61.
86. Vos SJ, Visser PJ, Verhey F, Aalten P, Knol D, et al. Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice.
PLoS One 2014;9:e100784.
87. Biomarkers for Alzheimer’s disease and Parkinson’s disease project of the Joint Programming Neurodegenerative Disease (JPND-
BIOMARKAPD) 2012. Available from: http://www.neurodegenerationresearch.eu/fileadmin/Project_Fact_Sheets/PDFs/Biomarkers/
BIOMARKAPD_Fact_Sheet_Template.pdf [Last accessed on 15 May 2020]
88. Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, et al. Consensus guidelines for lumbar puncture in patients with
neurological diseases. Alzheimers Dement 2017;8:111-26.
89. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, et al. Recommendations to standardize preanalytical confounding
factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012;6:419-30.
90. Le Bastard N, De Deyn PP, Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker
concentrations in cerebrospinal fluid. Clin Chem 2015;61:734-43.
91. Bourbouli M, Kapaki E, Petropoulou O, Paraskevas GP. Improved Performance of CSF dementia biomarker measurements over time: the
effect of quality control and harmonization programs. Biomark Applic 2018:BMAP-126.
92. Niemantsverdriet E, Goossens J, Struyfs H, Martin JJ, Goeman J, et al. Diagnostic impact of cerebrospinal fluid biomarker (pre-)
analytical variability in Alzheimer’s disease. J Alzheimers Dis 2016;51:97-106.
93. Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, et al. Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays:
analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clin
Biochem 2019;72:30-8.
94. Junttila A, Kuvaja M, Hartikainen P, Siloaho M, Helisalmi S, et al. Cerebrospinal fluid TDP-43 in frontotemporal lobar degeneration
and amyotrophic lateral sclerosis patients with and without the C9ORF72 hexanucleotide expansion. Dement Geriatr Cogn Dis Extra
2016;6:142-9.
95. Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides VC, et al. Cerebrospinal fluid TAR DNA-binding protein 43 combined
with Tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders. Dement
Geriatr Cogn Disord 2017;44:144-52.
96. Paraskevas GP, Bourbouli M, Zaganas I, Kapaki E. The emerging TDP-43 proteinopathy. Neuroimmunol Neuroinflammation 2018;5:17.
97. Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid
phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dementia 2015;1:505-12.
98. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of alpha-synuclein in cerebrospinal fluid as
a biomarker candidate: review of the literature and considerations for future studies. Biomark Med 2010;4:683-99.
99. Schade S, Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimers Res Ther 2014;6:72.
100. Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, et al. Decreased α-synuclein serum levels in patients with Lewy body dementia
compared to Alzheimer’s disease patients and control subjects. Dement Geriatr Cogn Disord 2011;31:413-6.
101. Aarsland D, Kurz M, Beyer M, Bronnick K, Piepenstock Nore S, et al. Early discriminatory diagnosis of dementia with Lewy bodies. The
emerging role of CSF and imaging biomarkers. Dement Geriatr Cogn Disord 2008;25:195-205.
102. Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K. The diagnostic value of CSF alpha-synuclein in the differential diagnosis of